More Than 270 Vaccines in Biopharmaceutical Pipeline Offer Hope to Prevent/Treat Wide Array of Diseases

Phrma.: 9/11/13

WASHINGTON, D.C. (September 11, 2013) – America’s biopharmaceutical companies are currently developing 271 vaccines to prevent – and in some cases treat – a variety of conditions, including infectious diseases, various forms of cancer and neurological disorders, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). The report is being released in conjunction with PhRMA’s 2013 Research and Hope Awards, which are honoring outstanding achievements in vaccine research and immunization by individuals and organizations in the medical innovation ecosystem.

For many years, vaccines have been used to successfully prevent devastating infectious diseases such as smallpox, measles and polio. According to data from the Centers for Disease Control and Prevention (CDC), 10 infectious diseases have been at least 90 percent eradicated in the United States as a result of vaccines. These innovations and subsequent immunization efforts have protected millions of children and families from needless illness. Read more